P&O Cruises cancellations: 35-night voyage on Ventura axed due to operational reasons
Cruise passengers have told of their disappointment after a 35 night cruise voyage onboard P&O's Ventura has been cancelled.
This comes after a 14 night cruise on Iona, scheduled to depart on August 30, 2026, had to be cancelled due to 'operational reasons'.
The latest cancellation has seen a voyage, departing January 4, 2027, pulled from Ventura's scheduled itinerary.
An email sent to customers wrote: "Due to operational reasons, we're sorry to inform you that your cruise, departing 4 January 2027, is no longer going ahead.
"We understand this news is disappointing and would like to apologise for the inconvenience this may cause.
"To avoid you missing out on your holiday, however, we've automatically transferred you to an alternative cruise, G701, on board Iona."
READ MORE: Redbridge flyover to close for emergency works this weekend
Many passengers have taken to Facebook to say they were disappointed that their planned trip was not going ahead.
A spokesperson for P&O told the Echo: "On occasion, it is necessary to change an itinerary from the one previously published and we are very sorry that Ventura's 35-night Caribbean itinerary departing January 04 2027, has been cancelled.
"Where possible, we are pleased to offer affected guests to transfer to Iona's similar Caribbean sailing across the same dates.
"Ventura will now offer three new itineraries, which go on sale on June 04, 2025."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
S&P and Moody's Upgrade Emaar's Credit Ratings, Citing Strong Financial Performance and Robust Revenue Visibility
DUBAI, UAE, June 11, 2025 /PRNewswire/ -- Emaar Properties PJSC (DFM: EMAAR), one of the world's most valuable and respected real estate development companies, has announced that both S&P Global Ratings and Moody's Ratings have upgraded the company's long-term issuer credit ratings, reinforcing Emaar's position as a financially resilient and strategically agile market leader. S&P Global Ratings upgraded its long-term issuer credit rating to BBB+ from BBB, while Moody's upgraded Emaar's long-term issuer rating to Baa1 from Baa2, both with stable outlooks. These upgrades reflect Emaar's robust financial fundamentals, consistent performance, and sound strategic direction. The same S&P and Moody's rating upgrade has been applied to Emaar's senior unsecured debt. As of March 2025, Emaar reported a revenue backlog of approximately US$ 34.6 billion, providing strong revenue and cash flow visibility through 2028. The company's recurring income portfolio continues to expand, supported by disciplined execution, resilient operations, and diversified income streams. S&P's upgrade was driven by Emaar's record-high backlog of US$ 29.9 billion as of December 2024, and healthy presales in the UAE of US$ 17.8 billion during 2024, alongside a net cash position, low leverage, and strong adjusted EBITDA margins. Moody's highlighted significant reduction in adjusted debt of Emaar from 2020 to March 2025 and the drop in debt-to-equity ratio over the same period. Mohamed Alabbar, Founder of Emaar, said: "We are proud to receive this recognition from both S&P and Moody's, which underscores the strength of our strategy, the quality of our assets, and the discipline we maintain in financial management. These upgrades reflect not only our performance, but also the confidence in Dubai's economy and real estate market. We will continue to pursue sustainable growth, innovation, and value creation for our shareholders and stakeholders alike." Emaar reported an interest coverage ratio of approximately 24 times for the year ending March 2025 and holds US$ 6.9 billion in cash (excluding escrow balances), along with US$ 2 billion in undrawn committed credit facilities, providing ample liquidity and financial flexibility. S&P noted that Emaar's strong mall, hospitality, and entertainment operations, in addition to the resilience of its real estate development business, contributed to the rating action. Dubai Mall recorded over 111 million visitors in 2024, with overall mall portfolio occupancy of 98.5%. These dual upgrades reinforce Emaar's reputation as a leading player in the global real estate sector. View original content: SOURCE Emaar Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Associated Press
21 minutes ago
- Associated Press
Zeteo Biomedical Secures Global Patents for Nasal and Ophthalmic Drug Delivery Device Innovations
CEDAR PARK, Texas, June 11, 2025 (SEND2PRESS NEWSWIRE) — Zeteo Biomedical, a privately held biomedical device company, today announced the issuance of new patents in the United States and European Union for its advanced drug delivery technologies. The patents, titled 'Cartridge Devices for Administration of a Medicament' (U.S. Patent No. 12329949) and 'Hand-Operated Devices for Administration of a Medicament' (EU Patent No. 3946526), further strengthen Zeteo's ZTech™ delivery platform portfolio for the administration of drugs and biologics via nasal, ophthalmic, and sublingual routes. These patented innovations advance Zeteo's ZTech-L™ and ZTech-P™ delivery systems, which include both single-use disposable and multi-dose, cartridge-reloadable handheld devices. The platforms support the administration of therapeutics in both liquid and dry powder formulations, including vaccines, biologics, and specialty drugs. Nasal delivery, in particular, is emerging as a highly effective, non-invasive alternative for treating conditions such as pain, emesis, seizures, neurodegenerative and autoimmune disorders, infectious diseases, and bioterror threats. 'We are seeing increasing global demand for metered-dose nasal, ophthalmic, and sublingual delivery devices that are compact, intuitive, and suitable for self-administration,' said Timothy Sullivan, CEO of Zeteo Biomedical. 'A unique feature that sets our device technology apart is its ability to function reliably in any physical orientation, making it ideal for medication delivery in both terrestrial and space-based microgravity environments. This capability opens exciting new frontiers for Zeteo including applications in space-based healthcare.' Zeteo's integrated delivery platforms and technical services streamline the development and commercial-scale production of patient-centric drug/device combination products for pharmaceutical and biotech partners. This focus on patient-friendly design improves treatment adherence and medical outcomes, while enhancing product differentiation and brand value for manufacturers. Zeteo's platform technologies are designed to meet the evolving demands of global and interstellar healthcare markets, delivering precision, performance, and portability for the next-generation of therapeutic drug/device combination products. About Zeteo Biomedical LLC Zeteo Biomedical is a Texas-based medical device company focused on the development and commercialization of advanced drug and biologic delivery systems. The company specializes in intranasal, ophthalmic, and sublingual delivery technologies designed to improve patient outcomes through precision dosing, portability, and ease of use. Zeteo's proprietary platforms are supported by an extensive patent portfolio and a range of product development services tailored to accelerate time to market for pharmaceutical and biotech clients worldwide. To learn more, visit MEDIA CONTACT: Cathy Diehl Zeteo Biomedical LLC +(1) 512-614-0144 [email protected] *LOGO link for media: NEWS SOURCE: Zeteo Biomedical LLC Keywords: Biotechnology, Zeteo Biomedical, drug delivery, vaccines, med tech, pharmaceuticals, biotech, public health, Nasal and Ophthalmic Drug Delivery Device, CEO Timothy Sullivan, CEDAR PARK, Texas This press release was issued on behalf of the news source (Zeteo Biomedical LLC) who is solely responsibile for its accuracy, by Send2Press® Newswire. Information is believed accurate but not guaranteed. Story ID: S2P126872 APNF0325A To view the original version, visit: © 2025 Send2Press® Newswire, a press release distribution service, Calif., USA. RIGHTS GRANTED FOR REPRODUCTION IN WHOLE OR IN PART BY ANY LEGITIMATE MEDIA OUTLET - SUCH AS NEWSPAPER, BROADCAST OR TRADE PERIODICAL. MAY NOT BE USED ON ANY NON-MEDIA WEBSITE PROMOTING PR OR MARKETING SERVICES OR CONTENT DEVELOPMENT. Disclaimer: This press release content was not created by nor issued by the Associated Press (AP). Content below is unrelated to this news story.
Yahoo
40 minutes ago
- Yahoo
Lammy holds Gibraltar talks ahead of potential EU deal
The foreign secretary has visited Gibraltar for talks ahead of a potential post-Brexit deal for the territory. David Lammy and Europe Minister Stephen Doughty met Gibraltar's chief minister Fabian Picardo and his cabinet on Wednesday, and the three are now heading to Brussels for discussions with EU and Spanish ministers. Talks on rules governing the border of Spain and Gibraltar have been ongoing since Britain left the European Union in 2020, but an agreement has not yet been reached. A Foreign Office source said that a deal was not yet finalised and that a number of sticking points remained. Writing on X, Picardo said it was "time to try to finalise arrangements for lasting, stable relationship between Gibraltar and the EU/Spain which is safe, secure and beneficial". Announcing the new UK-EU deal last month, Sir Keir Starmer and EU Council President António Costa said that the two were "not very far" from concluding a separate deal on Gibraltar. Gibraltar, which is a British Overseas Territory, is a 2.6 square mile headland to the south of Spain. The UK has had sovereignty over Gibraltar since 1713, although this is disputed by Spain, who claim the territory as their own. The territory's status and that of its border with Spain has been a key sticking point and has remained unresolved since Brexit. An estimated 15,000 people cross the Gibraltar-Spain border every day for work and leisure. Currently, Gibraltar residents can cross using residence cards without needing to have their passports stamped. Spanish citizens can cross using a government ID card. But there were concerns this would end with the introduction of the EU's Entry/Exit system later this year, causing huge delays at the border. Last month's deal UK-EU deal included confirmation there will be no legal barriers to UK citizens using e-gates, which should mean there won't be a return to passport stamping. But a separate Gibraltar deal could reportedly make the territory an associate member of the Schengen zone, allowing people to cross freely and see physical border infrastructure removed. Public opinion in Gibraltar, which has a population of 32,000 according to its government, is in favour of keeping British sovereignty. The most recent referendum, held in 2002, saw almost 99% of voters reject a proposal to share sovereignty with Spain.
